BTQ 1902
Glaucoma / Ocular Hypertension
Phase 2Active
Key Facts
About Novaliq
Novaliq is a private, clinical-stage biotech pioneering a novel, water-free drug delivery platform (EyeSol®) for ophthalmology. Its technology is designed to enhance drug bioavailability, retention time, and tolerability on the ocular surface. The company has achieved its first commercial approvals in the US for dry eye disease (NOV03, CyclASol) and is advancing a pipeline targeting glaucoma, diabetic retinopathy, dermatology, and uveitis. With a seasoned management team and strategic partnerships, Novaliq is positioned to challenge the standard of care in topical ocular therapeutics.
View full company profileTherapeutic Areas
Other Glaucoma / Ocular Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Evolute® Punctal Plug Delivery System | Mati Therapeutics | Unknown |
| iDose® TR (travoprost implant) | Glaukos | Commercial Launch |
| OTX-TIC | Ocular Therapeutix | Phase 1 |